Open calls and preannouncements

West African nations face pressing climate-related challenges, including environmental degradation, rainfall variability, extreme heatwaves, floods, and declining agricultural productivity. The accelerating impacts of climate change, along with socio-economic developments like population growth and urbanization, exacerbates climate-related challenges. The initiative “Climate Services for Risk Reduction in West Africa” (CS4RRA) was launched in 2023 by European countries in collaboration with West African institutions, including ACMAD, AGRHYMET/ CILSS, WASCAL, and the African Centres of Excellence. The aim of this initiative is to enhance climate resilience through Knowledge, Innovation, and Capacity Building (KIC), leveraging achievements from previous European Union and African Union programs (e.g., Horizon 2020, Joint Programme Initiative Climate/SINCERE, Copernicus CCS).

Research studies on therapies using small molecules, small non-coding chemically synthesized nucleic acid-based therapies, repurposed drugs or biologicals (e.g., antibodies or proteins such as enzymes, immune modulators or growth factors etc.). Proposals must cover at least one of the following areas:

On May 28th, 2025, more than 35 European and international funding agencies from 27 countries will launch the fourth European Clean Energy Transition Partnership (CETP) joint call. This call aims to support research and innovation activities related to the energy transition, a key challenge for the future of our planet. In France, the French National Research Agency (ANR) will co-fund this call together with the Pays de la Loire Region Council.

Charcot's disease, also known as amyotrophic lateral sclerosis (ALS), is a neurodegenerative disease caused by the progressive degeneration of the central and peripheral motor neurons in the brainstem and spinal cord that control voluntary muscles. It is the most common of the rare diseases, with 4 new cases diagnosed each day in France. Life expectancy is 3 to 5 years after the onset of the first symptoms, and to date, there is no cure available.